Skip to content

Latest

LUMIFY picks up Product Showcase award at TSE

LUMIFY picks up Product Showcase award at TSE

Bausch + Lomb announced that LUMIFY brimonidine tartrate ophthalmic solution 0.025% redness reliever eye drops were named a Product Showcase winner in the healthcare and over-the-counter (OTC) category at the National Association of Chain Drug Stores’ (NACDS) 2018 Total Store Expo.

Hallmark names Lai as senior VP and GM, Hallmark Labs/Digital

Hallmark names Lai as senior VP and GM, Hallmark Labs/Digital

Albert Lai has joined Hallmark Labs as senior vice president and general manager – Hallmark Labs/Digital. Lai brings more than 20 years of experience in the technology industry leading growth, development and strategy, most recently serving as chief technology officer for media at Brightcove.

Seasonal flu vaccinations now available at Giant Food

Seasonal flu vaccinations now available at Giant Food

Giant Food announced today that flu shots are once again available at all of its in-store pharmacies for both adults and children. The vaccinations are administered by Giant’s dedicated and certified in-store pharmacists and are often covered in-full by most insurance plans.

Walgreens buys pharmacy files from Fred’s

Walgreens buys pharmacy files from Fred’s

Walgreens and Fred’s announced today that they have entered into a definitive asset purchase agreement, where Walgreens will acquire pharmacy patient prescription files and related pharmacy inventory of 185 Fred’s stores located across 10 Southeastern states.

What to do about mounting transportation costs

What to do about mounting transportation costs

The high value of pharmaceutical shipments has traditionally meant that all parties in the chain drug industry were primarily concerned with quality. They needed a reliable, transparent solution. Given that shipping represented a tiny percentage of drug costs, price was a lesser concern.

Novartis to sell portions of Sandoz U.S. portfolio to Aurobindo

Novartis to sell portions of Sandoz U.S. portfolio to Aurobindo

Novartis today announced it has agreed to sell selected portions of its Sandoz U.S. portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, to Aurobindo Pharma USA Inc., for USD 0.9 billion of cash plus USD 0.1 billion of potential earn-outs.